Apr 19,2022

Freespira Earns Prestigious Quality Reaccreditation From Healthcare Quality Association on Accreditation

Freespira, Inc., maker of the first FDA-cleared digital therapeutic treatment to significantly reduce or eliminate panic attacks, panic disorder and post-traumatic stress disorder (PTSD) symptoms in only 28 days, today announced that it has received a highly coveted and significant quality reaccreditation from The Healthcare Quality Association on Accreditation (HQAA). This accreditation is also a necessary step for continuing access to third-party payment systems and the recently issued CMS code for digital therapeutics products.

PRODUCT

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Apr 20,2022

Latest DiGA Approval Makes HelloBetter Global Leader in Prescription Digital Therapeutics (PDTx)

HelloBetter Panic has recently secured approval as HelloBetter’s fifth DiGA (Digital Health Application), making the Panic programme becoming available for prescription in Germany. HelloBetter Panic offers straightforward and wait-free access to individualised psychological help for people suffering from panic disorders or agoraphobia with panic disorder.

PRODUCT

#reimbursement

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 13,2022

Orexo’s digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announced today it has been granted a Veteran Affairs Federal Supply Schedule (VA FFS) contract for deprexis®, an evidence-based digital therapy for the treatment of symptoms of depression. As of late July 2022, deprexis® will be reimbursed by the federal government and made available to federal healthcare providers, including Veterans Affairs (VA), Indian Health Service (IHS) and Department of Defense (DOD). The contract will expire in 2032.

PRODUCT

#cbt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Jul 26,2022

Hygieia announces new CPT codes for autonomous insulin dose titration

Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieia’s d-Nav® Technology. d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient’s changing insulin needs. Patients get the correct insulin dose at each injection, without the need for physician intervention.

PRODUCT

#reimbursement

#software

View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

Medicare Billing Codes For Digital Therapeutics: A Path Forward

Nearly five years have passed since the US Food and Drug Administration (FDA) cleared the first prescription digital therapeutic (PDT), and nearly another dozen have followed. PDTs are defined as FDA-cleared or -approved software-based medical devices, prescribed by a clinician, that are intended to prevent, manage, or treat a medical condition. Cleared PDTs to date span a range of clinical indications, from substance use disorder to ADHD to insomnia. Yet, to date, there is neither a Medicare benefit category nor a physician fee schedule for these products.

#pdt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Sep 07,2022

Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients

Orexo AB today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo’s evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking. During the last year, Orexo and Trinity Health have collaborated to establish new administrative processes and support systems to ensure effective patient access to these innovative digital therapies and reimbursement of the products through a collaborative care model.

COLLABORATION PARTNERSHIP

#institution

#cbt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Nov 02,2022

CureApp: Digital Therapeutic App for Hypertension Receives Insurance Coverage, Sales of the Service to Medical Institutions

CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake) announces the start of insurance coverage for its CureApp HT Hypertension Adjunctive Treatment App (hereafter, CureApp HT), a DTx^*1 solution treating hypertension, in Japan from September 1, 2022. Looking ahead, the app will be prescribed and provided to patients with hypertension as a health insurance treatment at medical institutions.

PRODUCT

#reimbursement

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 03,2022

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that the Wisconsin Department of Health Services (DHS) has entered into a contract for services with Pear to provide Wisconsin residents with access to Pear’s FDA-authorized PDTs reSET® and reSET-O® for the treatment of substance use disorder (SUD) and opioid use disorder (OUD), respectively. Eligible patients will be prescribed and treated with reSET or reSET-O to help communities throughout Wisconsin expand access to addiction care.

PRODUCT

#reimbursement

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Nov 29,2022

Digital Therapeutics (DTx) Market Report 2022: Unexplored Therapeutic Applications Presents Opportunities

The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. The adoption of digital therapeutics is growing at a fast pace owing to factors such as the rise in the number of patients with chronic diseases and growing investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and uneven payment models are challenging the growth of this market.

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Aug 15,2021

Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning a new HCPCS Level II code K1023 "Distal Transcutaneous Electrical Nerve Stimulator, Stimulates Peripheral Nerves of the Upper Arm." The coding decision covers Theranica's product Nerivio. The code will become effective on October 1, 2021.

PRODUCT

#reimbursement

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to REIMBURSEMENT